Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates and calculations
1.3.1 North America
1.3.2 Europe
1.3.3 Asia Pacific
1.3.4 Latin America
1.3.5 MEA
1.4 Forecast calculations
1.5 Data validation
1.6 COVID-19 impact analysis at global level
1.7 Data sources
1.7.1 Secondary
1.7.1.1 Paid sources
1.7.1.2 Unpaid sources
1.7.2 Primary
Chapter 2 Executive Summary
2.1 Sexual health testing market industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Device type trends
2.1.4 Application trends
2.1.5 End-use trends
Chapter 3 Sexual Health Testing Industry Insights
3.1 Industry segmentation
3.2 Industry ecosystem analysis
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Surge in prevalence of sexually transmitted diseases (STDs)
3.3.1.2 Increasing government initiatives towards STD's
3.3.1.3 Technological advancements in sexually transmitted disease diagnosis
3.3.1.4 Rising awareness regarding STDs and its diagnosis
3.3.2 Industry pitfalls & challenges
.3.3.2.1. Social taboo related to STDs
3.3.2.2 Lack of reimbursement scenario
3.4 Growth potential analysis
3.4.1 By device type
3.4.2 By application
3.4.3 By end-use
3.5 COVID- 19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive landscape
4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Competitive dashboard
4.4 Company market share, 2021
4.5 Competitive analysis of major market players
4.6 Competitive positioning matrix
4.7 Strategic outlook matrix
Chapter 5 Sexual Health Testing Market and Forecast, By Device Type (USD Million)
5.1 Key trends, by device type
1.1 Laboratory devices
1.1.1 PCR
1.1.2 Flow cytometers
1.1.3 Enzyme linked immunosorbent assay (ELISA)
1.1.4 Others
1.2 Point of care (PoC) devices
1.2.1 Microfluidics and immunochromatographic testing (ICT)
1.2.2 Rapid diagnostic kits
Chapter 6 Sexual Health Testing Market and Forecast, By Application (USD Million)
2.1 Key trends, by application
2.2 Chlamydia
2.3 Gonorrhoea
2.4 Syphilis
2.5 Genital herpes
2.6 Hepatitis B
2.7 HIV/AIDS
2.8 Others
Chapter 7 Sexual Health Testing Market and Forecast, By End-use (USD Million)
3.1 Key trends, by end-use
3.2 Hospitals
3.3 Diagnostic centers
3.4 Others
Chapter 8 Sexual Health Testing Market and Forecast, By Region (USD Million)
4.1 Key regional trends
4.2 North America
4.2.1 U.S.
4.2.2 Canada
4.3 Europe
4.3.1 Germany
4.3.2 UK
4.3.3 France
4.3.4 Spain
4.3.5 Italy
4.3.6 Russia
4.3.7 Poland
4.3.8 Switzerland
4.3.9 Norway
4.3.10 Finland
4.3.11 Sweden
4.3.12 Denmark
4.3.13 The Netherlands
4.4 Asia Pacific
4.4.1 China
4.4.2 Japan
4.4.3 India
4.4.4 Australia
4.4.5 South Korea
4.4.6 Taiwan
4.4.7 Indonesia
4.4.8 Vietnam
4.5 Latin America
4.5.1 Brazil
4.5.2 Mexico
4.5.3 Argentina
4.5.4 Colombia
4.5.5 Chile
4.6 Middle East & Africa
4.6.1 South Africa
4.6.2 Saudi Arabia
4.6.3 UAE
4.6.4 Israel
Chapter 9 Company Profiles
5.1 bioMérieux SA
5.2 Hologic, Inc.
5.3 OraSure Technologies, Inc.
5.4 Bio-Rad Laboratories, Inc.
5.5 Abbott Laboratories
5.6 Merck & Co. Inc.
5.7 Johnson & Johnson Services, Inc
5.8 GlaxoSmithKline Plc.
5.9 Allergen
5.10 Bayer AG
5.11 Bristol-Myers Squibb Company
5.12 Bausch Health Companies Inc.
5.13 Boehringer Ingelheim International GmbH
5.14 Sorrento Therapeutics, Inc.
5.15 WEX Pharmaceuticals Inc.
5.16 Zynerba Pharmaceuticals, Inc.
5.17 Medtronic Inc.
5.18 Boston Scientific Corporation
5.19 Halyard Health, Inc.
5.20 Neurotech Na, Inc.
